A Phase II multicenter single-armed study using subject-spesific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndrome-MDS
Principal investigator: Urpu Salmenniemi
HUS Helsinki University Hospital, Comprehensive Cancer Center
